Humacyte (NASDAQ:HUMA) Announces Earnings Results, Beats Estimates By $0.01 EPS

Humacyte (NASDAQ:HUMA) posted its quarterly earnings data on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01, Yahoo Finance reports. During the same period in the previous year, the firm posted ($0.21) EPS.

Humacyte Stock Down 8.1 %

Shares of HUMA stock opened at $3.31 on Friday. The company has a current ratio of 6.79, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. Humacyte has a twelve month low of $1.96 and a twelve month high of $5.60. The stock has a fifty day simple moving average of $3.50 and a two-hundred day simple moving average of $3.00.

Institutional Investors Weigh In On Humacyte

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Humacyte by 3.5% during the 4th quarter. Vanguard Group Inc. now owns 3,123,266 shares of the company’s stock worth $8,870,000 after purchasing an additional 104,299 shares during the last quarter. GSA Capital Partners LLP lifted its stake in shares of Humacyte by 22.8% during the 4th quarter. GSA Capital Partners LLP now owns 437,081 shares of the company’s stock worth $1,241,000 after purchasing an additional 81,163 shares during the last quarter. Barclays PLC lifted its stake in shares of Humacyte by 308.6% during the 4th quarter. Barclays PLC now owns 97,187 shares of the company’s stock worth $276,000 after purchasing an additional 73,399 shares during the last quarter. Wolverine Trading LLC lifted its stake in shares of Humacyte by 1,139.7% during the 4th quarter. Wolverine Trading LLC now owns 20,592 shares of the company’s stock worth $58,000 after purchasing an additional 18,931 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Humacyte during the 4th quarter worth $88,000. 27.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on HUMA shares. HC Wainwright started coverage on Humacyte in a report on Monday, December 11th. They set a “buy” rating and a $6.00 price objective for the company. Benchmark dropped their price objective on Humacyte from $16.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, December 27th.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).